Reach Us +44-1235-425476
A Study On Comparison Of Clinicsocial Profile With Staging Of Lung Carcinoma | 5747
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A study on comparison of clinicsocial profile with staging of lung carcinoma

International Conference on Pulmonary & Respiratory Medicine

Avinash G Adiga

ScientificTracks Abstracts: J Pulmon Resp Med

DOI: 10.4172/2161-105X.S1.002

Background: Chronic obstructive pulmonary disease (COPD) is associated with cardiovascular events (CVE), but its impact on overall mortality has not been well quantified. We determined the impact of global CVE risk assessment on total mortality in subjects with COPD. Methods: We examined the severity of COPD in 6,266 U.S. adults aged ≥40 years in relation to the estimated 10-year risk of CVE. COPD was defined by spirometry and severity was classified on the basis of forced expiratory volume in one second (FEV1): mild (FEV1 80%), moderate (50% FEV1<80%) or severe (FEV1<50%). Cox proportional hazards regression was used to evaluate the relationship of global CVE risk combined with COPD status to CVE and all-cause mortality over a mean follow-up of 98.8+/-51.3 months. Results: The proportion of individuals at high risk of CVE ranged from 25% (without COPD) to >50% (with moderate/severe COPD) (p<0.05). When global CVE risk scores were low, mortality was also low (<10/1000 person-years) regardless of COPD severity and mortality was high when CVE global risk was high (>50/1000 person-years). Global CVE risk improved prediction for both CVE and total mortality in COPD patients (p<0.0001) with a net reclassification improvement of 17.1% (p< 0.0001) and 13.0% (p<0.0001), respectively, beyond lung function measures. Conclusion: The addition of global CVE risk scores to lung function data significantly improves risk-stratification of COPD patients for CVE and total mortality and thus adds to predicting long-term survival of COPD patients